Izadifard Marzieh, Pashaiefar Hossein, Yaghmaie Marjan, Montazeri Maryam, Sadraie Maryam, Momeny Majid, Jalili Mahdi, Ahmadvand Mohammad, Ghaffari Seyed Hamidollah, Mohammadi Saeed, Alimoghaddam Kamran, Ghavamzadeh Ardeshir
1 Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences , Tehran, Iran .
2 Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences , Tehran, Iran .
Genet Test Mol Biomarkers. 2018 Oct;22(10):593-598. doi: 10.1089/gtmb.2018.0143. Epub 2018 Sep 14.
Recent evidence indicates that the PVT1, CCDC26, and CCAT1 long noncoding RNAs (lncRNAs) are involved in the leukemogenic process. This study quantified the expression levels of the PVT1, CCDC26, and CCAT1 lncRNAs in patients with acute myeloid leukemia (AML) and also correlated their expression levels with the clinicopathological features of the patients.
The expression levels of the PVT1, CCDC26, and CCAT1 lncRNAs were analyzed using quantitative reverse transcription-polymerase chain reaction of bone marrow specimens obtained from 86 AML patients, 48 AML-M3 patients, and 40 normal controls.
No differences were found between the combined AML patient populations and the healthy controls with respect to the expression levels of PVT1, CCDC26, and CCAT1 (p = 0.35, p = 0.09, and p = 0.77, respectively). However, compared with the controls, the AML-M3 patients had higher PVT1 expression (p = 0.017). Furthermore, high-risk AML-M3 patients manifested higher expression levels of PVT1 than low- and intermediate-risk groups. In addition, distinctive CCDC26 and CCAT1 expression levels were observed among patients with different French-American-British subtypes (p = 0.001 for CCDC26 and p = 0.013 for CCAT1). Compared with the healthy controls, AML-M4 and M5 had higher CCAT1 expression (p = 0.04) and AML-M2 and AML-M4/M5 patients had higher CCDC26 expression (p < 0.001 and p = 0.02, respectively). In addition, different patterns of CCDC26 expression were found among the different cytogenetic risk subtypes (p = 0.005). Finally, patients with intermediate cytogenetic risk showed higher CCDC26 expression levels.
The differential expression of the PVT1, CCDC26, and CCAT1 lncRNAs in different AML subtypes suggests that the deregulation of these transcripts may function in the multistep leukemogenic process and that they may serve as new therapeutic targets for this malignancy.
最近的证据表明，PVT1、CCDC26和CCAT1长链非编码RNA（lncRNA）参与白血病发生过程。本研究对急性髓系白血病（AML）患者中PVT1、CCDC26和CCAT1 lncRNA的表达水平进行了定量分析，并将其表达水平与患者的临床病理特征进行了关联。
采用定量逆转录-聚合酶链反应分析了86例AML患者、48例AML-M3患者和40例正常对照的骨髓标本中PVT1、CCDC26和CCAT1 lncRNA的表达水平。
在PVT1、CCDC26和CCAT1的表达水平上，AML患者合并群体与健康对照之间未发现差异（分别为p = 0.35、p = 0.09和p = 0.77）。然而，与对照组相比，AML-M3患者的PVT1表达更高（p = 0.0
